Agile Therapeutics Inc (NASDAQ:AGRX) has been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8.25.

A number of brokerages have recently commented on AGRX. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 price target on shares of Agile Therapeutics in a report on Thursday, September 21st. HC Wainwright set a $10.00 price target on Agile Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Friday, December 22nd. Royal Bank of Canada reissued a “buy” rating and set a $10.00 price target on shares of Agile Therapeutics in a report on Wednesday, October 18th. Finally, William Blair cut Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 26th.

A number of hedge funds have recently made changes to their positions in AGRX. Franklin Resources Inc. boosted its stake in Agile Therapeutics by 39.2% during the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after buying an additional 780,578 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after purchasing an additional 82,213 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Agile Therapeutics in the 2nd quarter valued at $309,000. Royal Bank of Canada boosted its position in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of Agile Therapeutics in the 2nd quarter valued at $205,000. 72.92% of the stock is owned by institutional investors and hedge funds.

Shares of Agile Therapeutics (AGRX) opened at $2.81 on Tuesday. Agile Therapeutics has a 52-week low of $1.93 and a 52-week high of $5.60. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $96.06, a price-to-earnings ratio of -3.05 and a beta of 2.00.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. equities analysts anticipate that Agile Therapeutics will post -0.97 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/09/agile-therapeutics-inc-agrx-receives-average-recommendation-of-buy-from-analysts.html.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.